Clinical Focus and Development Areas

TES HT100 is clinically evaluated as an adjunctive bedside tool to support early assessment, risk stratification and prioritization in adult patients with suspected intracranial abnormalities.

Current clinical evidence is focused on adult Emergency Department patients with mild head trauma and acute neurological symptoms, while additional applications of Temnography® technology are being explored through dedicated clinical development.

The ongoing TESCO programme prospectively evaluates TES HT100 against head CT within the standard clinical pathway. TES HT100 is designed to complement, not replace, definitive anatomical imaging.

A patient lying supine with the head inside the TES HT scanning chamber

Current Clinical Focus

Supported by the current prospective clinical programme (TESCO).

Adult patient in the Emergency Department→TES HT100 bedside assessment→Risk stratification and prioritization→CT / definitive imaging within the standard pathway

01

Head Trauma

Supporting early assessment and triage

In adult patients with mild head trauma, early identification of possible intracranial abnormalities can help healthcare professionals determine the appropriate clinical pathway and prioritize further diagnostic assessment.

TES HT100 provides a rapid, non-invasive bedside assessment designed to support risk stratification and triage before definitive imaging.

Head trauma represents one of the two adult patient populations currently being prospectively evaluated within the TESCO clinical programme.

02

Acute Neurological Symptoms

Additional information before diagnostic imaging

Adult patients presenting with acute neurological symptoms may require rapid evaluation to determine the need and priority for further imaging and specialist assessment.

TES HT100 is designed to provide additional objective information at the bedside, supporting earlier risk stratification while maintaining CT and the established diagnostic pathway as the reference for definitive anatomical assessment.

Acute neurological presentations constitute the second adult clinical cohort of the prospective TESCO programme.

Selected Scientific Publications

The clinical development of TES HT has progressed from early investigations of intracranial abnormalities to exploratory assessments in mild head trauma and the prospective TESCO programme. Peer-reviewed publications document this evolution and the growing body of clinical evidence for the TES HT platform in emergency assessment. These findings are interpreted within the populations and study designs reported in each publication.

  • Vaia et al. (2023)

    HT Temnography in the Early Diagnosis of Brain Lesions Due to Ischemic or Hemorrhagic Stroke

    International Journal of Advanced Research, 11(10), 191–195

    Original publication (opens in a new tab)

  • Montemerani et al. (2024)

    Reliability Evaluation of Temnography for Early Detection of Intracranial Lesions in Mild Traumatic Brain Injury Patient: A Preliminary Report of a New Portable, Non-Invasive Device

    Open Access Emergency Medicine, 16, 313–321

    Original publication (opens in a new tab)

  • Conte et al. (2026)

    Prospective Blinded Interim Evaluation of a Portable Radiofrequency Device TES HT to Support Triage in Emergency Department Patients with Mild Head Trauma or Acute Neurological Symptoms

    BMC Emergency Medicine, 26, 259

    Original publication (opens in a new tab)

Clinical Development

Potential roles requiring dedicated validation. These are not established clinical indications.

03

Stroke Pathway

Potential support for earlier patient assessment

Rapid identification of patients who may present intracranial structural abnormalities could provide useful additional information during the early stroke pathway, particularly before definitive imaging is available.

The potential role of Temnography® technology in supporting earlier assessment, patient prioritization and referral decisions represents an area of clinical development.

04

Patients under Thrombolytic Therapy

Potential monitoring application through repeat bedside assessment

Intracranial bleeding is an important clinical complication to consider in patients undergoing thrombolytic treatment.

Because Temnography® uses non-ionizing, very low-power RF sensing and allows repeat bedside assessment when clinically appropriate, the technology may offer opportunities for investigating monitoring strategies in this clinical setting.

This potential application requires dedicated clinical validation and appropriate regulatory assessment before it can be considered an established clinical use.

05

Neurological Rehabilitation

Potential role in repeat bedside assessment

Patients undergoing neurological rehabilitation may require further assessment if new or recurrent neurological symptoms occur.

The non-invasive and non-ionizing characteristics of Temnography® make repeat bedside assessment an area of potential clinical interest, subject to dedicated evaluation, validation and appropriate regulatory assessment.

Future Applications · Technology Pipeline

A broader technology platform

Temnography® is based on the measurement of tissue-specific electromagnetic behaviour using low-power broadband RF sensing.

Beyond the current TES HT100 clinical programme, the same Temnography® technology platform may support the development of additional applications through dedicated devices, algorithms and clinical validation.

  1. Temnography® technology core

    Low-power broadband RF sensing and computational analysis.

  2. TES HT family

    The first clinically advanced product family. TES HT100 is in the prospective TESCO programme.

  3. TES A series

    TES A90 and TES A100, registered medical devices in clinical development.

  4. Future applications

    Dedicated devices, algorithms and clinical validation.

TES A Series: Clinical development

TES A90 and TES A100 are registered medical devices within the Temnography® development pipeline for additional clinical applications. Dedicated clinical development and validation are ongoing to define their future clinical positioning.

Selected Scientific Publications

Research supporting the development of TES A explores the potential of low-power microwave measurements and computational imaging for assessing changes in brain tissue over time. Experimental investigations of the TES platform, together with independent research in microwave brain imaging, provide a scientific basis for continued technological development and future clinical evaluation.

Current evidence supports the evaluation of TES HT100 as an adjunctive bedside triage-support tool. Additional applications of Temnography® technology will require dedicated clinical development and appropriate regulatory assessment.

How TES® WorksExplore TES HT Products

TEMNOGRAPHY S.p.A. owns the Temnography® technology, including the related trademarks, patents and know-how. B&B S.r.l. has operated under mandate from TEMNOGRAPHY as manufacturer of the TES HT family and has been responsible for its clinical and regulatory development.